Non‐Invasive Fibrosis Testing in Adults With Obesity and MASLD : A Systematic Review and Meta‐Analysis
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11578-11590
DOI: 10.1111/dom.71357 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.09.2026. Verfasst von Patricia M Ortega und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Imperial College Healthcare NHS Trust, London, UK. Hauptthemen laut MEDLINE: Obesity, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Imperial Biomedical Research Centre, National Institute for Health and Care Research, Efficacy and Mechanism Evaluation Programme.
Abstract (Originalsprache)
Aims
Adults with obesity are at increased risk of metabolic dysfunction‐associated steatotic liver disease (MASLD)‐related fibrosis, but the diagnostic performance of non‐invasive tests (NITs) in this population remains uncertain. This meta‐analysis evaluated NITs for detecting significant (≥F2) and advanced (≥F3) fibrosis in adults with obesity and MASLD. Materials and Methods PubMed/MEDLINE, Embase, Web of Science and the Cochrane Library were searched from inception to 1 December 2025. Eligible studies enrolled adults with obesity (BMI ≥ 30 kg/m 2 ) and MASLD, compared an NIT with liver biopsy, and provided data to estimate sensitivity and specificity. Pooled estimates were derived using bivariate random‐effects models; HSROC curves were generated for each test and fibrosis threshold.
Results
Twenty‐seven studies including 5034 participants were included. Mean age was 40.6 ± 11.4 years and mean BMI was 43.3 ± 7.1 kg/m 2 . For significant fibrosis (≥F2), vibration‐controlled transient elastography (VCTE) showed a sensitivity of 0.64 (95% CI, 0.49–0.77) and specificity of 0.77 (95% CI, 0.66–0.85), with a median threshold of 7.95 kPa (IQR, 7.60–12.00). FIB‐4 showed broadly comparable performance, with a sensitivity of 0.65 (95% CI, 0.53–0.75) and specificity of 0.77 (95% CI, 0.64–0.86). For advanced fibrosis (≥F3), VCTE showed a sensitivity of 0.77 (95% CI, 0.67–0.85) and specificity of 0.84 (95% CI, 0.76–0.90), with a median threshold of 10.73 kPa (IQR, 8.15–12.80). Serum‐based tests showed more variable operating characteristics. Post hoc threshold analyses showed the expected trade‐off between sensitivity and specificity at lower VCTE cut‐offs.
Conclusions
In adults with obesity and MASLD, VCTE showed the most consistent diagnostic performance, particularly for advanced fibrosis, whereas serum‐based tests demonstrated more variable operating characteristics. Threshold selection and technical feasibility remain important determinants of performance, highlighting the need for validated obesity‐specific thresholds and diagnostic pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Imperial College Healthcare NHS Trust, London, UK.
- Bariatric Unit, Department of General Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
- Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust, London, UK.
- Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
- Area of Practice Improvement and Innovation in Nursing, Clínica Universidad de Navarra, Pamplona, Spain.
- Department of Surgery and Cancer, Imperial College London, London, UK.
ORCID-Profile: Chioma Izzi-Engbeaya
Förderung
- NIHR Imperial Biomedical Research Centre
- National Institute for Health and Care Research
- Efficacy and Mechanism Evaluation Programme
- Medical Research Council
Zitieren
APA
Ortega, P. M., Sabatella, L., Manousou, P., Arregui, A., Ahmed, A. R., & Izzi-Engbeaya, C. (2026). Non‐Invasive Fibrosis Testing in Adults With Obesity and MASLD : A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism, 28(12), 11578-11590. https://doi.org/10.1111/dom.71357
Vancouver
Ortega PM, Sabatella L, Manousou P, Arregui A, Ahmed AR, Izzi-Engbeaya C. Non‐Invasive Fibrosis Testing in Adults With Obesity and MASLD : A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026;28(12):11578-11590. doi:10.1111/dom.71357
BibTeX
@article{Ortega2026,
author = {Ortega, Patricia M and Sabatella, Lucas and Manousou, Pinelopi and Arregui, Adriana and Ahmed, Ahmed R and Izzi-Engbeaya, Chioma},
title = {Non‐Invasive Fibrosis Testing in Adults With Obesity and MASLD : A Systematic Review and Meta‐Analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11578--11590},
doi = {10.1111/dom.71357}
}
EUVIMED